Liposomal drug formulations for treatment of hematological malignancies
Expert Opin Pharmacother. 2023 Oct 12. doi: 10.1080/14656566.2023.2269086. Online ahead of print.NO ABSTRACTPMID:37823599 | DOI:10.1080/14656566.2023.2269086 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - October 12, 2023 Category: Drugs & Pharmacology Authors: Daniel Cacic H åkon Reikvam Source Type: research
The impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19
Expert Opin Pharmacother. 2023 Oct 12. doi: 10.1080/14656566.2023.2270421. Online ahead of print.NO ABSTRACTPMID:37823862 | DOI:10.1080/14656566.2023.2270421 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - October 12, 2023 Category: Drugs & Pharmacology Authors: Joseph E Blais Peng Wu Source Type: research
Response to: "the impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19"
Expert Opin Pharmacother. 2023 Oct 12. doi: 10.1080/14656566.2023.2270419. Online ahead of print.NO ABSTRACTPMID:37824089 | DOI:10.1080/14656566.2023.2270419 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - October 12, 2023 Category: Drugs & Pharmacology Authors: Matteo Bassetti Giorgia Brucci Antonio Vena Daniele Roberto Giacobbe Source Type: research
Liposomal drug formulations for treatment of hematological malignancies
Expert Opin Pharmacother. 2023 Oct 12. doi: 10.1080/14656566.2023.2269086. Online ahead of print.NO ABSTRACTPMID:37823599 | DOI:10.1080/14656566.2023.2269086 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - October 12, 2023 Category: Drugs & Pharmacology Authors: Daniel Cacic H åkon Reikvam Source Type: research
The impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19
Expert Opin Pharmacother. 2023 Oct 12. doi: 10.1080/14656566.2023.2270421. Online ahead of print.NO ABSTRACTPMID:37823862 | DOI:10.1080/14656566.2023.2270421 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - October 12, 2023 Category: Drugs & Pharmacology Authors: Joseph E Blais Peng Wu Source Type: research
Response to: "the impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19"
Expert Opin Pharmacother. 2023 Oct 12. doi: 10.1080/14656566.2023.2270419. Online ahead of print.NO ABSTRACTPMID:37824089 | DOI:10.1080/14656566.2023.2270419 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - October 12, 2023 Category: Drugs & Pharmacology Authors: Matteo Bassetti Giorgia Brucci Antonio Vena Daniele Roberto Giacobbe Source Type: research
Liposomal drug formulations for treatment of hematological malignancies
Expert Opin Pharmacother. 2023 Oct 12. doi: 10.1080/14656566.2023.2269086. Online ahead of print.NO ABSTRACTPMID:37823599 | DOI:10.1080/14656566.2023.2269086 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - October 12, 2023 Category: Drugs & Pharmacology Authors: Daniel Cacic H åkon Reikvam Source Type: research
The impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19
Expert Opin Pharmacother. 2023 Oct 12. doi: 10.1080/14656566.2023.2270421. Online ahead of print.NO ABSTRACTPMID:37823862 | DOI:10.1080/14656566.2023.2270421 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - October 12, 2023 Category: Drugs & Pharmacology Authors: Joseph E Blais Peng Wu Source Type: research
Response to: "the impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19"
Expert Opin Pharmacother. 2023 Oct 12. doi: 10.1080/14656566.2023.2270419. Online ahead of print.NO ABSTRACTPMID:37824089 | DOI:10.1080/14656566.2023.2270419 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - October 12, 2023 Category: Drugs & Pharmacology Authors: Matteo Bassetti Giorgia Brucci Antonio Vena Daniele Roberto Giacobbe Source Type: research
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis
This study assessed the clinical safety and efficacy of bexagliflozin, a sodium-glucose cotransporter 2(SGLT2) inhibitor, in managing glycemia among patients with type 2 diabetes mellitus (T2DM).AREAS COVERED: We examined RCTs with T2DM comparing the clinical effectiveness and safety of 20 mg once daily oral dose of bexagliflozin with placebo for managing glycemia till 28 May 2023, published on databases like ClinicalTrials.gov, PubMed, Embase, and Cochrane Library. Furthermore, reduction of body weight and systolic blood pressure (SBP) and the percentage of individuals who achieved glycated hemoglobin (HbA1c) of < 7% f...
Source: Expert Opinion on Pharmacotherapy - October 11, 2023 Category: Drugs & Pharmacology Authors: Sagar Dholariya Siddhartha Dutta Ragini Singh Deepak Parchwani Amit Sonagra Mehul Kaliya Source Type: research
The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder
This article reports the current evidence on the role of dopamine dysregulations in DD, the pharmacological profile of cariprazine, a partial agonist of D3 and D2 dopamine receptors, and first clinical observations that may support its usefulness in the therapy of DD. PubMed/MEDLINE was searched for the keywords 'cariprazine,' 'schizophrenia,' 'dual disorder,' 'dopamine,' and 'dopamine receptor.' Preclinical and clinical studies, and reviews published in English were retrieved.EXPERT OPINION: Although the management of DD remains challenging, and the evidence for pharmacologic treatments is still unsatisfactory, cariprazin...
Source: Expert Opinion on Pharmacotherapy - October 11, 2023 Category: Drugs & Pharmacology Authors: Heinz Grunze Source Type: research
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis
This study assessed the clinical safety and efficacy of bexagliflozin, a sodium-glucose cotransporter 2(SGLT2) inhibitor, in managing glycemia among patients with type 2 diabetes mellitus (T2DM).AREAS COVERED: We examined RCTs with T2DM comparing the clinical effectiveness and safety of 20 mg once daily oral dose of bexagliflozin with placebo for managing glycemia till 28 May 2023, published on databases like ClinicalTrials.gov, PubMed, Embase, and Cochrane Library. Furthermore, reduction of body weight and systolic blood pressure (SBP) and the percentage of individuals who achieved glycated hemoglobin (HbA1c) of < 7% f...
Source: Expert Opinion on Pharmacotherapy - October 11, 2023 Category: Drugs & Pharmacology Authors: Sagar Dholariya Siddhartha Dutta Ragini Singh Deepak Parchwani Amit Sonagra Mehul Kaliya Source Type: research
The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder
This article reports the current evidence on the role of dopamine dysregulations in DD, the pharmacological profile of cariprazine, a partial agonist of D3 and D2 dopamine receptors, and first clinical observations that may support its usefulness in the therapy of DD. PubMed/MEDLINE was searched for the keywords 'cariprazine,' 'schizophrenia,' 'dual disorder,' 'dopamine,' and 'dopamine receptor.' Preclinical and clinical studies, and reviews published in English were retrieved.EXPERT OPINION: Although the management of DD remains challenging, and the evidence for pharmacologic treatments is still unsatisfactory, cariprazin...
Source: Expert Opinion on Pharmacotherapy - October 11, 2023 Category: Drugs & Pharmacology Authors: Heinz Grunze Source Type: research
Migraine in multiple sclerosis patients: potential links and treatment approach
Expert Opin Pharmacother. 2023 Oct 9:1-7. doi: 10.1080/14656566.2023.2262384. Online ahead of print.ABSTRACTINTRODUCTION: Migraine has been reported to be twice as prevalent in patients with multiple sclerosis (MS) compared to the non-MS population. However, prospective, controlled studies that could lead to robust conclusions are still lacking.AREAS COVERED: Treatment of migraine in patients with MS can be challenging. Comorbidities need to be assessed and managed early, and preventive treatment should be initiated when indicated. Caution is warranted regarding the selection of the preventive medication since certain agen...
Source: Expert Opinion on Pharmacotherapy - October 9, 2023 Category: Drugs & Pharmacology Authors: Panagiotis Gklinos Dimos-Dimitrios Mitsikostas Source Type: research
